Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlinkTM technology, the first ADCs are addressing molecular targets for which ADCs have already shown at least clinical promises.
Mablink is currently developing three ADC programs:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
MBK-101
Acute Myeloid leukemia
Preclinical
MBK-102
Multiple Myeloma
Preclinical
MBK-103
Solid Tumors
Preclinical